In the last trading session, 11.47 million Seres Therapeutics Inc (NASDAQ:MCRB) shares changed hands as the company’s beta touched 2.01. With the company’s per share price at $0.92 changed hands at $0.09 or 10.44% during last session, the market valuation stood at $140.02M. MCRB’s last price was a discount, traded about -167.39% off its 52-week high of $2.46. The share price had its 52-week low at $0.54, which suggests the last value was 41.3% up since then. When we look at Seres Therapeutics Inc’s average trading volume, we note the 10-day average is 6.25 million shares, with the 3-month average coming to 4.18 million.
Analysts gave the Seres Therapeutics Inc (MCRB) stock a consensus recommendation rating of Buy, calculated at a mean rating of 2.33. If we narrow down to specifics, the data shows that 0 out of 3 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended MCRB as a Hold, 3 felt it is a Buy and 0 rated the stock as Underweight. Seres Therapeutics Inc’s EPS for the current quarter is expected to be -0.24.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Seres Therapeutics Inc (NASDAQ:MCRB) trade information
Instantly MCRB was in green as seen at the end of in last trading. With action -18.68%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -34.36%, with the 5-day performance at -18.68% in the red. However, in the 30-day time frame, Seres Therapeutics Inc (NASDAQ:MCRB) is 13.61% up. Looking at the short shares, we see there were 17.22 million shares sold at short interest cover period of 5.06 days.
The consensus price target for the stock as assigned by Wall Street analysts is 1.25, meaning bulls need an upside of 26.4% from its current market value. According to analyst projections, MCRB’s forecast low is 1.25 with 1.25 as the target high. To hit the forecast high, the stock’s price needs a -35.87% plunge from its current level, while the stock would need to soar -35.87% for it to hit the projected low.
Seres Therapeutics Inc (MCRB) estimates and forecasts
Data shows that the Seres Therapeutics Inc share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot 18.71% over the past 6 months, a -6.74% in annual growth rate that is considerably lower than the industry average of 17.70%.
The company’s revenue for the corresponding quarters a year ago was 1.87M and 64k respectively.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 18.22%. The 2024 estimates are for Seres Therapeutics Inc earnings to increase by 11.26%.
MCRB Dividends
Seres Therapeutics Inc is expected to release its next quarterly earnings report in October.
Seres Therapeutics Inc (NASDAQ:MCRB)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 5.44% of Seres Therapeutics Inc shares while 45.41% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 48.02%. There are 45.41% institutions holding the Seres Therapeutics Inc stock share, with FLAGSHIP PIONEERING INC. the top institutional holder. As of 2024-06-30, the company held 15.8226% of the shares, roughly 23.12 million MCRB shares worth $16.73 million.
FMR LLC holds the second largest percentage of outstanding shares, with 15.5489% or 22.72 million shares worth $16.44 million as of 2024-06-30.
